U.S. markets close in 1 hour 18 minutes
  • S&P 500

    3,846.67
    -6.40 (-0.17%)
     
  • Dow 30

    31,054.99
    -121.02 (-0.39%)
     
  • Nasdaq

    13,536.58
    +5.66 (+0.04%)
     
  • Russell 2000

    2,143.36
    +1.94 (+0.09%)
     
  • Crude Oil

    52.35
    -0.78 (-1.47%)
     
  • Gold

    1,855.90
    -10.00 (-0.54%)
     
  • Silver

    25.53
    -0.32 (-1.25%)
     
  • EUR/USD

    1.2179
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.0920
    -0.0170 (-1.53%)
     
  • GBP/USD

    1.3687
    -0.0044 (-0.32%)
     
  • USD/JPY

    103.8040
    +0.2990 (+0.29%)
     
  • BTC-USD

    33,496.86
    +3,013.12 (+9.88%)
     
  • CMC Crypto 200

    664.04
    +54.04 (+8.86%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Turkey says China's CoronaVac efficacy 91.25%, likely to increase

·1 min read

ANKARA, Dec 24 (Reuters) - A COVID-19 vaccine developed by China's Sinovac Biotech is 91.25% effective and the rate is likely to increase based on late-stage trial data, Turkish researchers said on Thursday, as the country becomes the second trial site to produce results for the Chinese candidate.

The researchers, part of the government's science council, said no major symptoms were detected during CoronaVac's trials in Turkey, apart from one person who had an allergic reaction.

Turkey had agreed to procure 50 million doses of Sinovac's CoronaVac by Dec. 11 but the shipment had been delayed. Health Minister Fahrettin Koca said the vaccines would arrive in Turkey on Monday, adding that Turkey would vaccinate some 9 million people in the first group, starting with health workers. (Reporting by Tuvan Gumrukcu and Ali Kucukgocmen; Editing by Alex Richardson)